Search in:

Advanced search

International Journal of Women's Health Volume 7, 2015 - Issue

Submit an article Journal homepage

Open access

Views

CrossRef citations to date

Altmetric

Original Research

History of cardiovascular events and cardiovascular risk factors among patients initiating strontium ranelate for treatment of osteoporosis

Jingbo Yu1 Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, USA

Jackson Tang2 Asclepius Analytics Ltd., Wanchai, Hong Kong

Zhiyi Li2 Asclepius Analytics Ltd., Wanchai, Hong Kong

Shiva Sajjan1 Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, USA

Christopher O’Regan3 Merck Sharp & Dohme Corp., Hoddeson, UK

Ankita Modi1 Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, USACorrespondence[email protected]

Vasilisa Sazonov1 Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, USA

show all

Pages 913-918 | Published online: 17 Nov 2015

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

CesareoRNapolitanoCIozzinoMStrontium ranelate in postmenopausal osteoporosis treatment: a critical appraisalInt J Womens Health201021621072291
PubMedGoogle Scholar
CianferottiLD’AstaFBrandiMLA review on strontium ranelate long-term antifracture efficacy in the treatment of postmenopausal osteoporosisTher Adv Musculoskelet Dis20135312713923858336
PubMedGoogle Scholar
StevensonMDavisSLloyd-JonesMBeverleyCThe clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal womenHealth Technol Assess2007114113417280622
PubMed Web of Science ®Google Scholar
European Medicines AgencyPSUR assessment report: Strontium ranelate2013 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000560/WC500147168.pdfAccessed March 31, 2014
Google Scholar
National Institute for Health and Clinical ExcellenceAlendronate, Etidronate, Risedronate, Raloxifene, Strontium Ranelate and Teriparatide for the Secondary Prevention of Osteoporotic Fragility Fractures in Postmenopausal Women (amended)LondonNational Health Service2008
Google Scholar
CooperCFoxKMBorerJSIschaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case-control study in the CPRDOsteoporos Int201425273774524322476
PubMed Web of Science ®Google Scholar
SvanstromHPasternakBHviidAUse of strontium ranelate and risk of acute coronary syndrome: cohort studyAnn Rheum Dis20147361037104324651624
PubMed Web of Science ®Google Scholar
European Medicines AgencyRecommendation to Restrict the Use of Protelos/Osseor (strontium ranelate)2013 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/04/WC500142507.pdfAccessed April 11, 2014
Google Scholar
DonneauAFReginsterJYCardiovascular safety of strontium ranelate: real-life assessment in clinical practiceOsteoporos Int201425239739824322477
PubMed Web of Science ®Google Scholar
European Medicines AgencyEuropean Medicines Agency Recommends that Protelos/Osseor Remain Available but with Further Restrictions2014 Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Protelos_and_Osseor/human_referral_prac_000025.jsp&mid=WC0b01ac05805c516fAccessed July 3, 2014
Google Scholar
AbrahamsenBGroveELVestergaardPNationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelateOsteoporos Int201425275776224322475
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

History of cardiovascular events and cardiovascular risk factors among patients initiating strontium ranelate for treatment of osteoporosis

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

History of cardiovascular events and cardiovascular risk factors among patients initiating strontium ranelate for treatment of osteoporosis

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date